Introduction
When a senior surgeon at Assam Medical College and Hospital (AMCH) allegedly refused to use medicines covered under the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM‑JAY) and later limited postoperative care, the incident quickly became a flashpoint for a broader debate about the reliability of India’s flagship health‑insurance scheme in the North‑East. While the episode itself involved a single patient’s family and a handful of operating‑theatre drugs, the reverberations touch on systemic issues: the capacity of public hospitals to deliver scheme‑approved treatment, the accountability mechanisms governing medical professionals, and the confidence of millions of beneficiaries who depend on subsidised care.
In a region where private health‑care options are scarce and out‑of‑pocket expenditure accounts for more than 60 % of total health spending, the AMCH probe is not merely a local controversy—it is a litmus test for the nation‑wide ambition to provide universal health coverage (UHC) through Ayushman Bharat. This article re‑examines the incident, situates it within the historical evolution of health insurance in India, analyses the data that reveal how often similar disputes arise, and draws lessons for policymakers, hospital administrators, and civil‑society watchdogs.
Main Analysis
1. Historical Context: From RSBY to Ayushman Bharat
The Rashtriya Swasthya Bima Yojana (RSBY), launched in 2008, was India’s first large‑scale attempt to pool risk across the poor and provide cashless hospitalization. By 2019, RSBY had enrolled roughly 40 million families, but coverage gaps and fragmented implementation limited its impact. Ayushman Bharat, introduced in September 2018, superseded RSBY with a more ambitious “universal” design: ≈10 % of the population (≈100 million families) are covered, and the scheme offers up to INR 5 lakhs per family per year for secondary and tertiary care.
Assam, with a poverty ratio of 31.9 % (Census 2011) and a per‑capita income below the national average, was an early adopter. The state signed a memorandum of understanding (MoU) with the National Health Authority (NHA) in 2019, committing to implement the scheme across 1,500 public hospitals, including AMCH—the premier tertiary‑care institution in the region.
2. Operational Mechanics of Ayushman Bharat in Public Hospitals
Under PM‑JAY, a patient’s eligibility is verified through a biometric check (Aadhaar) or a family ID. Once approved, the hospital receives a “claim” for the entire episode of care, irrespective of the actual drugs used, provided they are listed in the scheme’s “Standard Treatment Guidelines” (STGs). The hospital’s pharmacy is expected to stock the STG‑approved medicines, and the treating physician must document the usage in the online portal. Failure to comply can trigger claim rejections, delayed reimbursements, or penalties.
Data from the NHA’s 2023 annual report show that ≈78 % of claims from Assam were settled within 30 days, indicating a relatively efficient cash‑flow system. However, the same report flagged a “high incidence of claim rejections due to non‑adherence to STG protocols” in the North‑East, with a rejection rate of 12 % versus the national average of 7 %.
3. The AMCH Incident: Timeline Re‑Constructed
- June 10, 2024 – A patient’s relatives approached the surgical ward for a scheduled orthopedic operation. The attending surgeon allegedly informed them that the required intra‑operative drugs (e.g., tranexamic acid, cefuroxime) were not available under the Ayushman Bharat formulary.
- June 11 – The family was handed a list of “non‑scheme” medicines and asked to procure them independently, a request that would have added an estimated INR 12,000–15,000 to the cost.
- June 12 – After the family escalated the matter to the hospital’s senior administration, the surgeon reversed his stance, confirming that the drugs were indeed covered and the operation proceeded.
- June 13–17 – Post‑operative monitoring was reportedly limited to nursing staff; the surgeon did not conduct bedside rounds, unlike other patients in the same ward who received daily physician visits.
- June 18 – The family lodged a formal complaint with the state health department, prompting a “high‑level inquiry” by the Assam Health Ministry.
4. Why the Allegations Matter: Systemic Risks and Trust Deficit
Even if the surgeon’s actions were isolated, the incident highlights three systemic vulnerabilities:
- Supply‑Chain Gaps: Inconsistent stocking of STG‑approved medicines can force clinicians to either deviate from protocol or ask patients to purchase drugs privately, undermining the cash‑less promise of the scheme.
- Professional Accountability: The lack of a transparent audit trail for bedside visits creates a loophole where surgeons can claim compliance while providing sub‑optimal postoperative care.
- Beneficiary Awareness: Many patients are unaware of their rights under Ayushman Bharat, making them vulnerable to coercion or misinformation.
According to a 2022 survey by the Public Health Foundation of India (PHFI), ≈42 % of Ayushman Bharat beneficiaries in the North‑East reported “confusion” about the coverage of medicines, and 18 % said they had been asked to pay extra for drugs that should have been free.
5. Comparative Perspective: Similar Episodes Across India
AMCH is not an outlier. In 2023, a tertiary hospital in Uttar Pradesh faced a public outcry after a surgeon allegedly refused to use scheme‑covered insulin for a diabetic patient, demanding a private purchase instead. The incident led to a state‑wide audit that uncovered a 9 % non‑compliance rate in drug procurement across 45 hospitals.
Conversely, Kerala’s public health system, which boasts a 95 % compliance rate with Ayushman Bharat STGs, attributes its success to a robust “Drug Availability Dashboard” that updates inventory in real time and triggers automatic re‑ordering. The Kerala model demonstrates that technology‑enabled supply‑chain management can dramatically reduce the friction that fuels disputes like the AMCH case.
6. Economic Implications: Cost of Non‑Compliance
When a surgeon asks a patient to purchase non